Advocates in Europe aim to make hepatitis C medications more affordable.
Medical NGOs mounted a new legal bid on Monday to break a US pharma giant’s hold on a hepatitis C drug whose price — thousands of dollars for a typical course — has unleashed a fierce patent battle.
The drug, known by its lab name as sofosbuvir, cures 90 percent of Hep C cases, bringing hope for millions infected with the dangerous liver virus.
But critics say the manufacturer, Gilead Sciences, has priced it out of the reach of many patients and public health systems.
A single pill of the the drug, marketed as Sovaldi and other names, can cost up to $1,000 (R12,700). In France, a 12-week course of treatment costs 41,000 euros.
Read full article: Fresh battle over hepatitis C drug
|Read Full Article: Fresh battle over hepatitis C drug|